Regulatory · Sport
Peptides on the WADA Prohibited List, 2026 and 2027
Where each of the 696 compounds in our encyclopedia stands under the World Anti-Doping Agency's Prohibited List: named, caught by the S0 catch-all, unsettled, or not on the List. Under the 2027 List, which takes effect on January 1, 2027: 93 named on the List, 1 prohibited in competition only, 287 caught by S0 without being named, 114 unsettled, 201 not on the List.
Lists read September 27, 2026 · Rendered from our dataset on 2026-10-01 · By the Grey Peptides Editorial Board
Which List applies
The 2026 List has been in force since January 1, 2026, and is the one that applies today. WADA approved the 2027 List on September 10, 2026, published it on September 21, and it takes effect on January 1, 2027. What matters for an athlete is the List in force on the date of the sample, which is why this page shows both.
Four ways a peptide can stand
Named. A section of the List names the substance or a class that includes it. Most peptides that are named appear under S2, the section for peptide hormones, growth factors and related substances, and are prohibited at all times.
Caught by S0. S0 prohibits any pharmacological substance that no other section addresses and that has no current approval by any governmental regulatory health authority for human therapeutic use. The List's own examples include drugs under pre-clinical or clinical development or discontinued, and substances approved only for veterinary use. S0's text now lists “peptides” among its examples of non-approved substances. This is why most research peptides are prohibited although almost none is named: S0 reaches them because nobody has approved them.
Unsettled. Not named, and S0's test turns on a fact we have not settled: an approval somewhere outside the US that we have not verified, or an approval for diagnostic rather than therapeutic use. We say so rather than guess, and each row gives the reason.
Not on the List. Neither named nor caught by S0. Usually that is because the compound is approved somewhere for human therapeutic use and no section names it.
Specified or not
The List designates every prohibited substance as Specified except those in the sections it names as exceptions, and the distinction affects how a case is sanctioned under the World Anti-Doping Code. The List is explicit that a Specified substance should not in any way be considered less important or less dangerous than any other. The table gives the designation for every prohibited compound.
What changed for 2027
S0's text now lists “peptides” among its examples of non-approved substances. Compound by compound, against our records:
- Dermorphin: “Not on the 2026 List” became “Unsettled (S0 may apply)” for 2027. WADA monitored dermorphin as a non-prohibited substance in 2026 and dropped it from the 2027 Monitoring Program without adding it to the List; on its face S0 would cover it.
Named on the List (93)
The List names the substance, or a class that plainly includes it, in a section. Where it is named, the List's own words are quoted.
Show all 93
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| ACE-031 | Prohibited at all times (S4.3) | Non-Specified | The List: “Decoy activin receptors (e.g. ACE-031)” |
| Alexamorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “alexamorelin” |
| Anamorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “anamorelin” |
| AOD-9604 | Prohibited at all times (S2.2.3) | Non-Specified | The List: “AOD-9604” Named as a growth hormone fragment, alongside hGH 176-191. |
| Apitegromab | Prohibited at all times (S4.3) | Non-Specified | The List: “apitegromab” |
| ARA-290 | Prohibited at all times (S2.1.5) | Non-Specified | ARA-290 (cibinetide) is an EPO-derived peptide that activates the innate repair receptor, the class S2.1.5 names. |
| Azagly-nafarelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | A GnRH agonist analogue, caught by S2.2.1's class wording; it is approved only for animals. |
| Bimagrumab | Prohibited at all times (S4.3) | Non-Specified | The List: “bimagrumab” |
| BPC-157 | Prohibited at all times (S0) | Specified | The List: “BPC-157” It is the first substance S0 names, on page 4 of both Lists. |
| Buserelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “buserelin” |
| Capromorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “capromorelin” |
| CJC-1293 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “CJC-1293” |
| CJC-1295 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “CJC-1295” Named alongside CJC-1293 as a GHRH analogue. |
| Corticorelin | Prohibited at all times (S2.2.2) | Non-Specified | The List: “corticorelin” |
| Corticotropin | Prohibited at all times (S2.2.2) | Non-Specified | The List: “Corticotrophins” |
| Deslorelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “deslorelin” |
| Desmopressin | Prohibited at all times (S5) | Specified | The List: “Desmopressin” |
| Eftansomatropin alfa | Prohibited at all times (S2.2.3) | Non-Specified | A long-acting growth hormone; prohibited under S2 whatever its approval status. |
| Equine Chorionic Gonadotropin | Prohibited in males, at all times (S2.2.1) | Non-Specified | A chorionic gonadotrophin, caught by S2.2.1's wording in males; it is approved only for animals. |
| Erythropoietin (EPO) | Prohibited at all times (S2.1.1) | Non-Specified | The List: “erythropoietins (EPO)” |
| Felypressin | Prohibited at all times (S5) | Specified | The List: “Local administration of felypressin in dental anaesthesia” The List mentions felypressin only to exempt local dental use; given any other way it is an S5 masking agent. |
| Follistatin-315 | Prohibited at all times (S4.3) | Non-Specified | The List: “e.g. follistatin, myostatin propeptide” Named as an example of the myostatin-binding proteins. |
| Follistatin-344 | Prohibited at all times (S4.3) | Non-Specified | The List: “e.g. follistatin, myostatin propeptide” Named as an example of the myostatin-binding proteins. |
| Garetosmab | Prohibited at all times (S4.3) | Non-Specified | An anti-activin A antibody. |
| Ghrelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “lenomorelin (ghrelin)” |
| GHRP-1 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “GHRP-1” |
| GHRP-2 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “GHRP-2 (pralmorelin)” |
| GHRP-4 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “GHRP-4” |
| GHRP-5 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “GHRP-5” |
| GHRP-6 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “GHRP-6” |
| Gonadorelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “GnRH, gonadorelin” |
| Gonadorelin (6-D-Phe) | Prohibited in males, at all times (S2.2.1) | Non-Specified | A GnRH agonist analogue, caught by S2.2.1's class wording; it is approved only for animals. |
| Goserelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “goserelin” |
| Growth hormone-releasing hormone | Prohibited at all times (S2.2.4) | Non-Specified | The List: “growth hormone-releasing hormone (GHRH)” |
| HCG | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “chorionic gonadotrophin (CG)” |
| Hexarelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “examorelin (hexarelin)” |
| Histrelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “histrelin” |
| IGF-1 | Prohibited at all times (S2.3) | Non-Specified | The List: “Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues” |
| IGF-1 DES(1-3) | Prohibited at all times (S2.3) | Non-Specified | A truncated IGF-1 that also occurs naturally in small amounts. |
| IGF-1 LR3 | Prohibited at all times (S2.3) | Non-Specified | — |
| Insulin aspart | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin degludec | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin degludec / liraglutide (IDegLira) | Prohibited at all times (S4.4.2) | Non-Specified | Contains insulin degludec, prohibited as a class under S4.4.2; its liraglutide is not listed. |
| Insulin detemir | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin efsitora alfa | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin glargine | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin glargine / lixisenatide (iGlarLixi) | Prohibited at all times (S4.4.2) | Non-Specified | Contains insulin glargine, prohibited as a class under S4.4.2; its lixisenatide is not listed. |
| Insulin glulisine | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin icodec | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin lispro | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin peglispro | Prohibited at all times (S4.4.2) | Non-Specified | — |
| Insulin tregopil | Prohibited at all times (S4.4.2) | Non-Specified | — |
| Ipamorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “ipamorelin” |
| Kisspeptin-10 | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “kisspeptin and its agonist analogues” |
| Kisspeptin-54 | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “kisspeptin and its agonist analogues” |
| Lecirelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | A GnRH agonist analogue, caught by S2.2.1's class wording; it is approved only for animals. |
| Leuprolide | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “leuprorelin” |
| Lixivaptan | Prohibited at all times (S5) | Specified | A vaptan: S5 names the class and three of its members. |
| Lonapegsomatropin | Prohibited at all times (S2.2.3) | Non-Specified | The List: “lonapegsomatropin” A long-acting growth hormone analogue. |
| Lutropin alfa | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “luteinizing hormone (LH)” Lutropin alfa is recombinant human LH. |
| Macimorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “macimorelin” |
| Mecasermin | Prohibited at all times (S2.3) | Non-Specified | The List: “IGF-1, mecasermin” |
| Mecasermin rinfabate | Prohibited at all times (S2.3) | Non-Specified | A complex of mecasermin, which the List names, with its binding protein IGFBP-3. |
| Menotropin | Prohibited in males, at all times (S2.2.1) | Non-Specified | Human menopausal gonadotrophin contains LH activity, and LH is named; FDA approval does not lift an S2 listing. |
| MGF | Prohibited at all times (S2.3) | Non-Specified | The List: “Mechano growth factors (MGFs)” |
| MK-677 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “ibutamoren (MK-677)” |
| Mod GRF 1-29 | Prohibited at all times (S2.2.4) | Non-Specified | A GHRH analogue sold as “CJC-1295 without DAC”; the List names CJC-1293 and CJC-1295 and covers every GHRH analogue. |
| MOTS-c | Prohibited at all times (S4.4.1) | Non-Specified | The List: “mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)” Listed as an AMPK activator alongside AICAR, not under S2 as is often claimed. |
| Nafarelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “nafarelin” |
| NPH insulin (isophane) | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Peforelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | A GnRH agonist analogue, caught by S2.2.1's class wording; it is approved only for animals. |
| PEG-MGF | Prohibited at all times (S2.3) | Non-Specified | PEG-MGF itself is not named: it is a pegylated mechano growth factor, caught by S2's rule covering substances of similar chemical structure or biological effect. |
| Peginesatide | Prohibited at all times (S2.1.1) | Non-Specified | The List: “peginesatide” |
| Pegmolesatide | Prohibited at all times (S2.1.1) | Non-Specified | The List: “pegmolesatide” |
| Porcine Insulin Zinc Suspension | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class. |
| Regular human insulin | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Relamorelin | Prohibited at all times (S2.2.4) | Non-Specified | A ghrelin-receptor agonist, the receptor the named secretagogues act on. |
| Sermorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “sermorelin” |
| Somapacitan | Prohibited at all times (S2.2.3) | Non-Specified | The List: “somapacitan” A long-acting growth hormone analogue. |
| Somatrem | Prohibited at all times (S2.2.3) | Non-Specified | — |
| Somatrogon | Prohibited at all times (S2.2.3) | Non-Specified | The List: “somatrogon” A long-acting growth hormone analogue. |
| Somatropin (HGH) | Prohibited at all times (S2.2.3) | Non-Specified | The List: “Growth hormone (GH), its analogues and fragments” Approval does not exempt a substance from the List. |
| Sometribove | Prohibited at all times (S2.2.3) | Non-Specified | A bovine growth hormone analogue, caught by S2.2.3's class wording. |
| Sotatercept | Prohibited at all times (S2.1.4) | Non-Specified | The List: “sotatercept” |
| Tabimorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “tabimorelin” |
| Taldefgrobep alfa | Prohibited at all times (S4.3) | Non-Specified | An anti-myostatin adnectin: S4.3 prohibits myostatin inhibitors. |
| TB-500 | Prohibited at all times (S2.3) | Non-Specified | The List: “Thymosin-ß4 and its derivatives e.g. TB-500” |
| Tesamorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “tesamorelin” FDA-approved and WADA-prohibited at the same time: the two regimes are unrelated. |
| Tetracosactide | Prohibited at all times (S2.2.2) | Non-Specified | The List: “tetracosactide” |
| Thymosin β4 | Prohibited at all times (S2.3) | Non-Specified | The List: “Thymosin-ß4 and its derivatives” |
| Trafermin | Prohibited at all times (S2.3) | Non-Specified | Fibroblast growth factor 2 is caught by S2.3's class wording. |
| Trevogrumab | Prohibited at all times (S4.3) | Non-Specified | An anti-myostatin antibody. |
| Triptorelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “triptorelin” |
Prohibited in competition only (1)
Named in a section that applies only in competition.
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| Tesofensine | Prohibited in competition (S6.B) | Specified | The List: “Tesofensine” |
Not named, but caught by S0 (287)
Not named anywhere, and approved nowhere for human therapeutic use, so S0, the catch-all, applies.
Show all 287
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| 3PRGD2 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| 5-Amino-1MQ | Prohibited (S0 catch-all) | Specified | — |
| Adamax | Prohibited (S0 catch-all) | Specified | — |
| Adipotide | Prohibited (S0 catch-all) | Specified | — |
| Adrenomedullin | Prohibited (S0 catch-all) | Specified | — |
| Adrenomedullin 2 | Prohibited (S0 catch-all) | Specified | — |
| Adropin | Prohibited (S0 catch-all) | Specified | — |
| AHK-Cu | Prohibited (S0 catch-all) | Specified | — |
| Albiglutide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| AlF-NOTA-octreotide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Alfatide II | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Alpha-MSH | Prohibited (S0 catch-all) | Specified | — |
| Amilomotide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Amycretin | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Amylin | Prohibited (S0 catch-all) | Specified | — |
| Angiotensin-(1-7) | Prohibited (S0 catch-all) | Specified | — |
| Apamin | Prohibited (S0 catch-all) | Specified | — |
| Apelin | Prohibited (S0 catch-all) | Specified | — |
| Apraglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Avexitide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Avorelin | Prohibited (S0 catch-all) | Specified | An investigational drug never brought to market: S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. |
| AZD6234 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Azetirelin | Prohibited (S0 catch-all) | Specified | An investigational drug never brought to market: S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. |
| B7-33 | Prohibited (S0 catch-all) | Specified | — |
| Balixafortide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Beta-Endorphin | Prohibited (S0 catch-all) | Specified | — |
| Bofanglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Bradykinin | Prohibited (S0 catch-all) | Specified | — |
| Brimapitide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| BRN2 (POU3F2) Research Peptide | Prohibited (S0 catch-all) | Specified | — |
| Bronchogen | Prohibited (S0 catch-all) | Specified | — |
| C-peptide | Prohibited (S0 catch-all) | Specified | — |
| Cagrilintide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| CagriSema | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Canvuparatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Cardiogen | Prohibited (S0 catch-all) | Specified | — |
| Cartalax | Prohibited (S0 catch-all) | Specified | — |
| Cathelicidin | Prohibited (S0 catch-all) | Specified | — |
| Cecropin | Prohibited (S0 catch-all) | Specified | — |
| Cenderitide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Cerluten | Prohibited (S0 catch-all) | Specified | — |
| Certepetide | Prohibited (S0 catch-all) | Specified | Not named on the List and with no performance link, but S0 reaches any substance with no current approval by any government regulator, and certepetide has none. |
| CGRP | Prohibited (S0 catch-all) | Specified | — |
| Chonluten | Prohibited (S0 catch-all) | Specified | — |
| Cilengitide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| CNP | Prohibited (S0 catch-all) | Specified | — |
| Colulintide | Prohibited (S0 catch-all) | Specified | An investigational drug with no approval by any government regulator, which is what S0 reaches; it is not named on the List. |
| Cortagen | Prohibited (S0 catch-all) | Specified | — |
| Cortistatin | Prohibited (S0 catch-all) | Specified | Not approved by any regulator for human therapeutic use, which is what S0 covers. |
| Cotadutide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| CP04 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Cyclic Glycine-Proline | Prohibited (S0 catch-all) | Specified | — |
| Cyclo(His-Pro) | Prohibited (S0 catch-all) | Specified | — |
| D-4F | Prohibited (S0 catch-all) | Specified | — |
| Dalazatide | Prohibited (S0 catch-all) | Specified | Never approved anywhere we found: S0 covers substances with no current government approval for human use. |
| Danegaptide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Danuglipron | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Dapiglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| DAPTA | Prohibited (S0 catch-all) | Specified | Not named on the List and with no performance link, but S0 reaches any substance with no current approval by any government regulator, and DAPTA has none. |
| Davunetide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Dazdotuftide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Dermcidin | Prohibited (S0 catch-all) | Specified | — |
| Detirelix | Prohibited (S0 catch-all) | Specified | An investigational drug never brought to market: S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. |
| Dihexa | Prohibited (S0 catch-all) | Specified | — |
| Dirucotide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Disomotide | Prohibited (S0 catch-all) | Specified | Not named on the List and with no performance link, but S0 reaches any substance with no current approval by any government regulator, and disomotide has none. |
| Dolcanatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| DOTA-EB-TATE | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| DOTA-LM3 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| DOTA-MGS5 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| DOTAMTATE | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| DOTANOC | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| DSIP | Prohibited (S0 catch-all) | Specified | — |
| Dusquetide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Dynorphin | Prohibited (S0 catch-all) | Specified | — |
| Ebiratide | Prohibited (S0 catch-all) | Specified | Never approved, and its development ended: S0's own examples include discontinued drugs. |
| ECC5004 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Edratide | Prohibited (S0 catch-all) | Specified | Never approved anywhere we found: S0 covers substances with no current government approval for human use. |
| Efinopegdutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Efmedaglutide alfa | Prohibited (S0 catch-all) | Specified | An investigational drug with no approval by any government regulator, which is what S0 reaches; it is not named on the List. |
| Efocipegtrutide | Prohibited (S0 catch-all) | Specified | An investigational drug with no approval by any government regulator, which is what S0 reaches; it is not named on the List. |
| Efpeglenatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Elabela | Prohibited (S0 catch-all) | Specified | — |
| Eloralintide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Elpamotide | Prohibited (S0 catch-all) | Specified | Not named on the List and with no performance link, but S0 reaches any substance with no current approval by any government regulator, and elpamotide has none. |
| Elsiglutide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Emodepside | Prohibited (S0 catch-all) | Specified | Used only in veterinary medicine: S0's own wording covers substances approved only for veterinary use. |
| Endoluten | Prohibited (S0 catch-all) | Specified | — |
| Endomorphin-1 | Prohibited (S0 catch-all) | Specified | — |
| Endothelin-1 | Prohibited (S0 catch-all) | Specified | — |
| Eneboparatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Enicepatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Enkephalin | Prohibited (S0 catch-all) | Specified | — |
| Enterostatin | Prohibited (S0 catch-all) | Specified | — |
| Epithalamin | Prohibited (S0 catch-all) | Specified | — |
| Epithalon | Prohibited (S0 catch-all) | Specified | — |
| FAP-2286 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Feline Interferon Omega | Prohibited (S0 catch-all) | Specified | Used only in veterinary medicine: S0's own wording covers substances approved only for veterinary use. |
| Fexapotide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| FGL Peptide | Prohibited (S0 catch-all) | Specified | — |
| FK-13 | Prohibited (S0 catch-all) | Specified | — |
| Fluciclatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Forigerimod | Prohibited (S0 catch-all) | Specified | Never approved anywhere we found: S0 covers substances with no current government approval for human use. |
| FOXO4-DRI | Prohibited (S0 catch-all) | Specified | — |
| FPPRGD2 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Galacto-RGD | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Galanin | Prohibited (S0 catch-all) | Specified | — |
| Galinpepimut-S | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Gastrin | Prohibited (S0 catch-all) | Specified | — |
| Gastrin-releasing peptide | Prohibited (S0 catch-all) | Specified | — |
| GDF11 | Prohibited (S0 catch-all) | Specified | — |
| GDF15 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| GHK-Cu | Prohibited (S0 catch-all) | Specified | — |
| GIP | Prohibited (S0 catch-all) | Specified | — |
| Glepaglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Glicentin | Prohibited (S0 catch-all) | Specified | — |
| GLP-2 | Prohibited (S0 catch-all) | Specified | — |
| Glypromate | Prohibited (S0 catch-all) | Specified | — |
| GMA106 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| GnRF Analogue–Diphtheria Toxoid Conjugate | Prohibited (S0 catch-all) | Specified | Used only in veterinary medicine: S0's own wording covers substances approved only for veterinary use. |
| Goralatide | Prohibited (S0 catch-all) | Specified | Not approved by any regulator for human therapeutic use, which is what S0 covers. |
| Guanylin | Prohibited (S0 catch-all) | Specified | — |
| hBD-1 | Prohibited (S0 catch-all) | Specified | — |
| hBD-2 | Prohibited (S0 catch-all) | Specified | — |
| hBD-3 | Prohibited (S0 catch-all) | Specified | — |
| HD5 | Prohibited (S0 catch-all) | Specified | — |
| HD6 | Prohibited (S0 catch-all) | Specified | — |
| Histatin | Prohibited (S0 catch-all) | Specified | — |
| HM15136 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| HM15275 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| HNP-1 | Prohibited (S0 catch-all) | Specified | — |
| HRS-9531 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Humanin | Prohibited (S0 catch-all) | Specified | — |
| Indolicidin | Prohibited (S0 catch-all) | Specified | — |
| INSL5 | Prohibited (S0 catch-all) | Specified | Not named on the list; as a peptide with no approval for human use anywhere it falls under S0, non-approved substances. |
| Irisin | Prohibited (S0 catch-all) | Specified | — |
| Iseganan | Prohibited (S0 catch-all) | Specified | Never approved, and its development ended: S0's own examples include discontinued drugs. |
| Klotho Peptide | Prohibited (S0 catch-all) | Specified | — |
| KN056 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| KPV | Prohibited (S0 catch-all) | Specified | — |
| KR-12 | Prohibited (S0 catch-all) | Specified | — |
| Kyotorphin | Prohibited (S0 catch-all) | Specified | — |
| Lactoferricin | Prohibited (S0 catch-all) | Specified | — |
| Lancovutide | Prohibited (S0 catch-all) | Specified | Not named on the List and with no performance link, but S0 reaches any substance with no current approval by any government regulator, and lancovutide has none. |
| Larazotide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Leconotide | Prohibited (S0 catch-all) | Specified | Not named on the List and not an analgesic class the List restricts, but S0 reaches any substance with no current approval by any government regulator, and leconotide has none. |
| Livagen | Prohibited (S0 catch-all) | Specified | — |
| Livoletide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| LL-37 | Prohibited (S0 catch-all) | Specified | — |
| LSALT peptide | Prohibited (S0 catch-all) | Specified | An investigational drug with no approval by any government regulator, which is what S0 reaches; it is not named on the List. |
| Lusupultide | Prohibited (S0 catch-all) | Specified | Not named on the list; as a substance with no approval for human use anywhere it falls under S0, non-approved substances. |
| Magainin | Prohibited (S0 catch-all) | Specified | — |
| Maraciclatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Maridebart cafraglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Melanin-concentrating hormone | Prohibited (S0 catch-all) | Specified | — |
| Melanocyte-stimulating hormone beta | Prohibited (S0 catch-all) | Specified | — |
| Melanotan II | Prohibited (S0 catch-all) | Specified | — |
| Melittin | Prohibited (S0 catch-all) | Specified | — |
| Modimelanotide | Prohibited (S0 catch-all) | Specified | Not named on the List and with no performance link, but S0 reaches any substance with no current approval by any government regulator, and modimelanotide has none. |
| Montirelin | Prohibited (S0 catch-all) | Specified | An investigational drug never brought to market: S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. |
| Motilin | Prohibited (S0 catch-all) | Specified | — |
| Murabutide | Prohibited (S0 catch-all) | Specified | Never approved anywhere we found: S0 covers substances with no current government approval for human use. |
| Muramyl Dipeptide | Prohibited (S0 catch-all) | Specified | — |
| Murepavadin | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| NA-Selank Amidate | Prohibited (S0 catch-all) | Specified | — |
| Nangibotide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Nelipepimut-S | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Nemifitide | Prohibited (S0 catch-all) | Specified | Never approved, and its development ended: S0's own examples include discontinued drugs. |
| Nendratareotide Uzatansine | Prohibited (S0 catch-all) | Specified | An investigational drug with no approval by any regulator: S0's own examples include drugs under clinical development. |
| NeoB | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Nerinetide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Nesfatin-1 | Prohibited (S0 catch-all) | Specified | — |
| Neurokinin A | Prohibited (S0 catch-all) | Specified | — |
| Neurokinin B | Prohibited (S0 catch-all) | Specified | — |
| Neuromedin S | Prohibited (S0 catch-all) | Specified | Not named on the list; as a peptide with no approval for human use anywhere it falls under S0, non-approved substances. |
| Neuromedin U | Prohibited (S0 catch-all) | Specified | — |
| Neuropeptide S | Prohibited (S0 catch-all) | Specified | — |
| Neuropeptide Y | Prohibited (S0 catch-all) | Specified | — |
| Neurotensin | Prohibited (S0 catch-all) | Specified | — |
| Nociceptin | Prohibited (S0 catch-all) | Specified | — |
| NODAGA-exendin-4 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Nosiheptide | Prohibited (S0 catch-all) | Specified | Used only in veterinary medicine: S0's own wording covers substances approved only for veterinary use. |
| NPAS3 Research Peptide | Prohibited (S0 catch-all) | Specified | — |
| Obestatin | Prohibited (S0 catch-all) | Specified | — |
| Obinepitide | Prohibited (S0 catch-all) | Specified | An investigational drug with no approval by any government regulator, which is what S0 reaches; it is not named on the List. |
| Olatorepatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Omiganan | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Orexin-A | Prohibited (S0 catch-all) | Specified | — |
| Orexin-B | Prohibited (S0 catch-all) | Specified | — |
| Osteocalcin | Prohibited (S0 catch-all) | Specified | — |
| Osteogenic growth peptide | Prohibited (S0 catch-all) | Specified | — |
| Ovagen | Prohibited (S0 catch-all) | Specified | — |
| Oxyntomodulin | Prohibited (S0 catch-all) | Specified | An endogenous peptide with no approval as a medicine; S0 covers substances not approved for human therapeutic use. |
| Ozarelix | Prohibited (S0 catch-all) | Specified | Not named on the List; S2.2.1 covers GnRH and its agonist analogues, not antagonists, but S0 reaches any substance with no current approval by any government regulator, and ozarelix has none. |
| P21 | Prohibited (S0 catch-all) | Specified | — |
| PACAP | Prohibited (S0 catch-all) | Specified | An endogenous peptide with no approval as a medicine; S0 covers substances not approved for human therapeutic use. |
| Pancragen | Prohibited (S0 catch-all) | Specified | Not approved by any regulator for human therapeutic use, which is what S0 covers. |
| Pancreatic polypeptide | Prohibited (S0 catch-all) | Specified | — |
| Parathyroid hormone-related protein | Prohibited (S0 catch-all) | Specified | — |
| PB-718 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| PE-22-28 | Prohibited (S0 catch-all) | Specified | — |
| Pegbovigrastim | Prohibited (S0 catch-all) | Specified | Used only in veterinary medicine: S0's own wording covers substances approved only for veterinary use. |
| Pegsebrenatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Pemvidutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Pentixafor | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Pentixather | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| PEPITEM | Prohibited (S0 catch-all) | Specified | Not approved by any regulator for human therapeutic use, which is what S0 covers. |
| Peptide YY | Prohibited (S0 catch-all) | Specified | — |
| Petrelintide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Pexiganan | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| PHM-27 | Prohibited (S0 catch-all) | Specified | Not approved by any regulator for human therapeutic use, which is what S0 covers. |
| Pinealon | Prohibited (S0 catch-all) | Specified | — |
| Plectasin | Prohibited (S0 catch-all) | Specified | — |
| PNC-27 | Prohibited (S0 catch-all) | Specified | — |
| Porcine FSH | Prohibited (S0 catch-all) | Specified | Used only in veterinary medicine: S0's own wording covers substances approved only for veterinary use. |
| Posatirelin | Prohibited (S0 catch-all) | Specified | Never approved, and its development ended: S0's own examples include discontinued drugs. |
| Preptin | Prohibited (S0 catch-all) | Specified | — |
| Prostamax | Prohibited (S0 catch-all) | Specified | — |
| Protirelin | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| PSMA I&S | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Ramoplanin | Prohibited (S0 catch-all) | Specified | Never approved, and its development ended: S0's own examples include discontinued drugs. |
| Relaxin-3 | Prohibited (S0 catch-all) | Specified | Not named on the list; as a peptide with no approval for human use anywhere it falls under S0, non-approved substances. |
| Retatrutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| RM2 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Rotigaptide | Prohibited (S0 catch-all) | Specified | A discontinued investigational antiarrhythmic peptide with no approval by any regulator for human therapeutic use; such substances fall under the catch-all S0 (non-approved substances). Not named on any Prohibited List. |
| Rovatirelin | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Rusalatide | Prohibited (S0 catch-all) | Specified | Never approved: a pharmacological substance with no current approval for human therapeutic use. |
| Ruxotemitide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| SAR-bisPSMA | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| SARTATE | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Satoreotide Tetraxetan | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Satoreotide Trizoxetan | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Seglitide | Prohibited (S0 catch-all) | Specified | An investigational drug never brought to market: S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. |
| Selepressin | Prohibited (S0 catch-all) | Specified | An investigational vasopressin analogue never approved for human use; S0 covers substances with no current approval. |
| Serelaxin | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| SHLP2 | Prohibited (S0 catch-all) | Specified | — |
| SHLP6 | Prohibited (S0 catch-all) | Specified | — |
| SiTATE | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Solnatide | Prohibited (S0 catch-all) | Specified | Not named on the List and with no performance link, but S0 reaches any substance with no current approval by any government regulator, and solnatide has none. |
| Sonefpeglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Spexin | Prohibited (S0 catch-all) | Specified | — |
| Substance P | Prohibited (S0 catch-all) | Specified | — |
| Surotomycin | Prohibited (S0 catch-all) | Specified | Never approved, and its development ended: S0's own examples include discontinued drugs. |
| Survodutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Taspoglutide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Tecemotide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Technetium Tc 99m Etarfolatide | Prohibited (S0 catch-all) | Specified | Never approved: its EU marketing application was withdrawn in 2014, and Drugs@FDA holds no record. |
| Teixobactin | Prohibited (S0 catch-all) | Specified | — |
| Teprotide | Prohibited (S0 catch-all) | Specified | — |
| Testagen | Prohibited (S0 catch-all) | Specified | — |
| Teverelix | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Thiostrepton | Prohibited (S0 catch-all) | Specified | Used only in veterinary medicine: S0's own wording covers substances approved only for veterinary use. |
| Thymoctonan | Prohibited (S0 catch-all) | Specified | Never approved, and its development ended: S0's own examples include discontinued drugs. |
| Thymomodulin | Prohibited (S0 catch-all) | Specified | — |
| Thymopentin | Prohibited (S0 catch-all) | Specified | — |
| Thymostimulin | Prohibited (S0 catch-all) | Specified | — |
| Thymulin | Prohibited (S0 catch-all) | Specified | — |
| Tifuvirtide | Prohibited (S0 catch-all) | Specified | Not named on the list; as a peptide with no approval for human use anywhere it falls under S0, non-approved substances. |
| Tiplimotide | Prohibited (S0 catch-all) | Specified | Never approved anywhere we found: S0 covers substances with no current government approval for human use. |
| Tozuleristide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Trivehexin | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Trofolastat | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Tuftsin | Prohibited (S0 catch-all) | Specified | — |
| Ubiquicidin 29-41 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| UBT251 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Ularitide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Ulimorelin | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. Ghrelin receptor agonists also appear under S2.2.4 (growth hormone secretagogues) when they release growth hormone; ulimorelin is not named. |
| Urocortin | Prohibited (S0 catch-all) | Specified | — |
| Urocortin 2 | Prohibited (S0 catch-all) | Specified | — |
| Uroguanylin | Prohibited (S0 catch-all) | Specified | — |
| Urotensin II | Prohibited (S0 catch-all) | Specified | — |
| Utreglutide | Prohibited (S0 catch-all) | Specified | An investigational drug with no approval by any government regulator, which is what S0 reaches; it is not named on the List. |
| Vapreotide | Prohibited (S0 catch-all) | Specified | No government approval found: an unapproved drug falls under S0. |
| Veldoreotide | Prohibited (S0 catch-all) | Specified | Not named on the List. Growth-hormone secretagogues and releasing factors are named in S2, but veldoreotide lowers growth hormone rather than raising it; S0 reaches any substance with no current approval by any government regulator, and veldoreotide has none. |
| Ventfort | Prohibited (S0 catch-all) | Specified | — |
| Vessel dilator | Prohibited (S0 catch-all) | Specified | — |
| Vesugen | Prohibited (S0 catch-all) | Specified | — |
| Vilon | Prohibited (S0 catch-all) | Specified | Not approved by any regulator for human therapeutic use, which is what S0 covers. |
| Virginiamycin | Prohibited (S0 catch-all) | Specified | Used only in veterinary medicine: S0's own wording covers substances approved only for veterinary use. |
| Visoluten | Prohibited (S0 catch-all) | Specified | — |
| VK2735 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| VMT-α-NET | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Xenin | Prohibited (S0 catch-all) | Specified | — |
| Zadavotide Guraxetan | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Zelenectide Pevedotin | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Zelpultide alfa | Prohibited (S0 catch-all) | Specified | An investigational drug with no approval by any government regulator, which is what S0 reaches; it is not named on the List. |
| Zoptarelin Doxorubicin | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
Unsettled (114)
Not named, and whether S0 applies turns on a fact this site has not settled, such as an approval outside the US or an approval for diagnostic use only. Each row says which.
Show all 114
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| Abarelix | Unsettled (S0 may apply) | Specified | Withdrawn from the US market in 2005; our entry notes it is still sold in some markets, which we have not verified. A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. |
| Acetyl Decapeptide-3 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Dipeptide-1 Cetyl Ester | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Dipeptide-3 Aminohexanoate | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Heptapeptide-4 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Hexapeptide-1 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Hexapeptide-30 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Hexapeptide-37 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Hexapeptide-38 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Hexapeptide-49 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Hexapeptide-51 Amide | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Octapeptide-3 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Pentapeptide-1 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl SH-Heptapeptide-1 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-11 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-15 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-2 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-22 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-3 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-5 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-9 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tripeptide-1 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| ANP | Unsettled (S0 may apply) | Specified | The same molecule as carperitide, which is approved in Japan (Hanp). |
| Aprotinin | Unsettled (S0 may apply) | Specified | Discontinued in the US; whether it is approved in other countries now has not been verified. An antifibrinolytic with no performance action; S0 applies only if no government health authority currently approves it. |
| Argireline | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Beinaglutide | Unsettled (S0 may apply) | Specified | — |
| Biotinoyl Tripeptide-1 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Capreomycin | Unsettled (S0 may apply) | Specified | Discontinued in the US; whether it is still approved in other countries has not been verified. An antibacterial with no anabolic or performance action; S0 applies only if no government health authority currently approves it. |
| Caprooyl Tetrapeptide-3 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Carperitide | Unsettled (S0 may apply) | Specified | — |
| Cerebrolysin | Unsettled (S0 may apply) | Specified | — |
| Ceruletide | Unsettled (S0 may apply) | Specified | Discontinued in the US; whether any other country still approves it has not been verified. A cholecystokinin analogue with no anabolic or performance action; S0 applies only if no government health authority currently approves it. |
| Cholecystokinin | Unsettled (S0 may apply) | Specified | Its octapeptide form, sincalide, is FDA-approved as a diagnostic agent; S0 speaks of approval for therapeutic use. |
| Cortexin | Unsettled (S0 may apply) | Specified | — |
| Decapeptide-12 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Dermorphin | Unsettled (S0 may apply) | Specified | WADA monitored dermorphin as a non-prohibited substance in 2026 and dropped it from the 2027 Monitoring Program without adding it to the List; on its face S0 would cover it. 2026: Not on the 2026 List |
| Desirudin | Unsettled (S0 may apply) | Specified | Discontinued in the US; whether it is still approved in other countries has not been verified. An anticoagulant with no performance action; S0 applies only if no government health authority currently approves it. |
| Dipeptide-2 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Ecnoglutide | Unsettled (S0 may apply) | Specified | — |
| Efruxifermin | Unsettled (S2.3 may apply) | Non-Specified | The List prohibits 'Fibroblast growth factors (FGFs)' under S2.3 without naming FGF21 analogues; whether that class reaches an investigational FGF21 analogue made for liver disease has not been ruled on, and if it does not, S0 would apply as to any unapproved drug. |
| Efsubaglutide alfa | Unsettled (S0 may apply) | Specified | Approved in China (NMPA, announced June 11, 2025). S0 covers substances with no government approval, so it should not reach an approved drug, and GLP-1 agonists are not named on the List; marked unsettled, as for the other China-only GLP-1 agonists on this site, until the List's treatment of drugs approved in one country is reviewed. |
| GLP-1 | Unsettled (S0 may apply) | Specified | Not named on the list. S0 covers substances with no approval for human therapeutic use; native GLP-1 has none in the US, but beinaglutide, a recombinant human GLP-1, is used as a medicine, so whether S0 applies is unsettled, as on that entry. |
| Glutathione | Unsettled (S0 may apply) | Specified | Sold as a supplement and compounded for injection, never approved as a drug; how S0 treats it has not been decided. Separately, any infusion or injection of more than 100 mL per 12 hours is a prohibited method (M2.2) unless received in hospital treatment, surgery or clinical investigations. |
| Hexanoyl Dipeptide-3 Norleucine Acetate | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Hexapeptide-10 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Hexapeptide-11 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Hexapeptide-33 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Hexapeptide-9 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| HYNIC-TOC | Unsettled (S0 may apply) | Specified | Not approved by FDA or EMA; authorisations by individual European national agencies were not checked, and S0 applies only if no government health authority approves it. |
| Lepirudin | Unsettled (S0 may apply) | Specified | Withdrawn in the EU in 2012 and absent from Drugs@FDA; whether any country approves it now has not been verified. An anticoagulant with no performance action; S0 applies only if no government health authority currently approves it. |
| Leuphasyl | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Lucinactant | Unsettled (S0 may apply) | Specified | Discontinued in the US and never authorised in the EU; whether any country approves it now has not been verified. A lung surfactant with no performance action; S0 applies only if no government health authority currently approves it. |
| Lypressin | Unsettled (S0 may apply) | Specified | Discontinued in the US; whether any other country still approves it has not been verified. Vasopressin analogues are not named on the List; S0 applies only if no government health authority currently approves it. |
| Mazdutide | Unsettled (S0 may apply) | Specified | — |
| Myristoyl Hexapeptide-16 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Myristoyl Pentapeptide-17 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Myristoyl Tetrapeptide-12 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| NAD+ | Unsettled (S0 may apply) | Specified | Not a peptide. Sold as a supplement and compounded for injection, never approved as a drug; how S0 treats it has not been decided. Separately, any infusion or injection of more than 100 mL per 12 hours is a prohibited method (M2.2) unless received in hospital treatment, surgery or clinical investigations. |
| Nesiritide | Unsettled (S0 may apply) | Specified | FDA-approved as Natrecor (NDA 020920, August 10, 2001) and now discontinued in the US; whether an approval is current anywhere is not verified here. |
| Nonapeptide-1 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Noopept | Unsettled (S0 may apply) | Specified | — |
| Octapeptide-2 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Oligopeptide-68 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Ornipressin | Unsettled (S0 may apply) | Specified | Used in European clinical studies; whether it is approved in any country now has not been verified, so whether S0 reaches it is not settled. |
| Pal-GHK | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Dipeptide-10 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Dipeptide-5 Diaminohydroxybutyrate | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Dipeptide-7 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Hexapeptide-12 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Hexapeptide-14 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Pentapeptide-4 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tetrapeptide-10 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tetrapeptide-20 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tetrapeptide-7 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tripeptide-28 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tripeptide-38 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tripeptide-5 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tripeptide-8 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Parathyroid hormone (1-84) | Unsettled (S0 may apply) | Specified | Not named on the List. Natpara (BLA 125511) is no longer supplied in the US after December 31, 2025, and the EU authorisation of Natpar was withdrawn on July 1, 2026 (EMA); whether an approval is current anywhere else is not verified here. |
| Pegbelfermin | Unsettled (S2.3 may apply) | Non-Specified | The List prohibits 'Fibroblast growth factors (FGFs)' under S2.3 without naming FGF21 analogues; whether that class reaches an investigational FGF21 analogue made for liver disease has not been ruled on, and if it does not, S0 would apply as to any unapproved drug. |
| Pegozafermin | Unsettled (S2.3 may apply) | Non-Specified | The List prohibits 'Fibroblast growth factors (FGFs)' under S2.3 without naming FGF21 analogues; whether that class reaches an investigational FGF21 analogue made for liver disease has not been ruled on, and if it does not, S0 would apply as to any unapproved drug. |
| Pegvisomant | Unsettled (S2.2.3 may apply) | Non-Specified | A modified growth hormone that blocks the GH receptor. S2.2.3 covers growth hormone analogues and S2 covers substances of similar chemical structure; the List does not say whether that reaches an antagonist. |
| Pentagastrin | Unsettled (S0 may apply) | Specified | Discontinued in the US; whether any other country still approves it has not been verified. A diagnostic gastrin analogue with no anabolic or performance action; S0 applies only if no government health authority currently approves it. |
| Pentapeptide-3 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Pentapeptide-31 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Polyethylene glycol loxenatide | Unsettled (S0 may apply) | Specified | Used to treat type 2 diabetes in China according to published Chinese trials; we have not verified an approval with China's regulator, so whether S0 reaches it is not settled. |
| Pramlintide | Unsettled (S0 may apply) | Specified | Symlin (NDA 021332) is discontinued in the US; no current approval elsewhere is verified here. |
| Prostatilen | Unsettled (S0 may apply) | Specified | Used as a medicine in Russia according to the cited studies. S0 covers substances with no approval by any government health authority; whether a medicine used only there falls under it has not been decided. |
| PSMA-1007 | Unsettled (S0 may apply) | Specified | Not approved by FDA or EMA; authorised nationally in ten EEA countries and Switzerland (verified October 29, 2026). An approval anywhere takes a substance out of S0, but the site does not read foreign approvals either way. |
| Recombinant Human Endostatin | Unsettled (S0 may apply) | Specified | Reported approved in China by peer-reviewed papers; the NMPA register was not read. By the List's words an approval anywhere takes a substance out of S0, but this site does not read foreign approvals either way. |
| Retinalamin | Unsettled (S0 may apply) | Specified | Used as a medicine in Russia according to the cited studies. S0 covers substances with no approval by any government health authority; whether a medicine used only there falls under it has not been decided. |
| Romurtide | Unsettled (S0 may apply) | Specified | Marketed in Japan as Nopia; the current Japanese package-insert index lists no product, so whether a current approval exists for S0 purposes was not confirmed from a Japanese regulator record. |
| Selank | Unsettled (S0 may apply) | Specified | — |
| Semax | Unsettled (S0 may apply) | Specified | — |
| Syn-Ake | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Taltirelin | Unsettled (S0 may apply) | Specified | Approved in Japan; whether that approval is current for S0 purposes was not confirmed from a Japanese regulator record. |
| Terlipressin | Unsettled (S5 may apply) | Specified | Not named. Terlipressin is a prodrug of lysine-vasopressin; S5 names the analogue desmopressin and covers substances with a similar biological effect, without saying whether that reaches terlipressin. |
| Tertomotide | Unsettled (S0 may apply) | Specified | Not named on the List. Not approved in the US or EU; whether a government elsewhere has approved it was not established from the sources read, and S0 applies only to a substance no government has approved for human use. |
| Tetrapeptide-1 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Tetrapeptide-21 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Tetrapeptide-26 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Tetrapeptide-30 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Thrombomodulin Alfa | Unsettled (S0 may apply) | Specified | Approved in Japan (PMDA list of approved products); by the List's words an approval anywhere takes a substance out of S0, but this site does not read foreign approvals either way. |
| Thymalin | Unsettled (S0 may apply) | Specified | — |
| Thymodepressin | Unsettled (S0 may apply) | Specified | Reported registered as a drug in Russia by its developers' peer-reviewed review; the Russian state register was not read. By the List's words an approval anywhere takes a substance out of S0, but this site does not read foreign approvals either way. |
| Thymogen | Unsettled (S0 may apply) | Specified | — |
| Thymosin α1 | Unsettled (S0 may apply) | Specified | — |
| Trifluoroacetyl Tripeptide-2 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Tripeptide-10 Citrulline | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Tripeptide-29 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Tripeptide-32 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Vasopressin | Unsettled (S5 may apply) | Specified | Not named. S5 names desmopressin, a vasopressin analogue, and covers substances with a similar biological effect; the List does not say whether vasopressin itself is one. |
| VIP | Unsettled (S0 may apply) | Specified | Not named. VIP is approved outside the US in at least one combination product: Invicorp (aviptadil with phentolamine, injected into the penis for erectile dysfunction), authorised in France on October 5, 2018 through the EU mutual-recognition procedure (HAS transparency committee opinion, September 4, 2019) and accepted for restricted use in NHS Scotland on December 11, 2017 (SMC 1284/17). Read October 28, 2026. |
Not on the List (201)
Neither named nor caught by S0, usually because the compound is approved somewhere for human therapeutic use and no section names it.
Show all 201
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| Abaloparatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Aclerastide | Not on the 2027 List | — | A topical wound-healing peptide acting on the Mas receptor; not a class WADA lists. 2026: Not on the 2026 List |
| Adrenorphin (Metorphamide) | Not on the 2027 List | — | An endogenous opioid peptide studied as a research compound; not itself named on the WADA Prohibited List. Opioids are addressed elsewhere on the List as a drug class. 2026: Not on the 2026 List |
| Afamelanotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Agouti-Related Peptide (AgRP) | Not on the 2027 List | — | An endogenous hunger neuropeptide acting on melanocortin receptors; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Alamandine | Not on the 2027 List | — | An endogenous renin-angiotensin-system peptide studied as a research compound; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Albuvirtide | Not on the 2027 List | — | Not named on the List. Licensed in China, so the S0 catch-all for substances with no government approval does not apply; an antiretroviral with no performance-enhancing action. 2026: Not on the 2026 List |
| Alprostadil | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Angiotensin II | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Anidulafungin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Anserine | Not on the 2027 List | — | A naturally occurring dietary histidine dipeptide; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Apidaecin | Not on the 2027 List | — | Honeybee research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Arenicin | Not on the 2027 List | — | Marine-lugworm research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Asprosin | Not on the 2027 List | — | An endogenous fasting hormone regulating glucose and appetite; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Atosiban | Not on the 2027 List | — | Not named, and the European Medicines Agency lists Tractocile (EU authorisation January 20, 2000) and the generic Atosiban SUN as currently authorised (EMA medicines database, read October 3, 2026), so S0, which reaches only substances with no current approval anywhere, does not apply. 2026: Not on the 2026 List |
| Augurin (ECRG4) | Not on the 2027 List | — | An endogenous ECRG4-derived secreted tumor-suppressor peptide; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Aurein | Not on the 2027 List | — | Bell-frog-skin research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Bacitracin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Balenine | Not on the 2027 List | — | A compound found in food or formed from food protein, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Beta-Casomorphin-7 (BCM-7) | Not on the 2027 List | — | A food-derived opioid peptide formed during milk digestion; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Beta-lipotropin | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Bioactive Food Peptides | Not on the 2027 List | — | A food or supplement ingredient, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Bivalirudin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Bleomycin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| BNP | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; as a drug it exists only as nesiritide, whose WADA position is set out in that entry. 2026: Not on the 2026 List |
| Bombesin | Not on the 2027 List | — | An amphibian research peptide probing satiety and gastric function; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Botulinum Toxin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Brevinin | Not on the 2027 List | — | Frog-skin research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Buforin | Not on the 2027 List | — | A research antimicrobial/cell-penetrating peptide; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Bulevirtide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Calcitonin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Carbetocin | Not on the 2027 List | — | Not named, and the UK's electronic medicines compendium carries a current Summary of Product Characteristics for Pabal (carbetocin; Ferring, PL 03194/0058, first authorised October 6, 1997, text revised September 16, 2026; read October 5, 2026), so S0, which reaches only substances with no current approval anywhere, does not apply. 2026: Not on the 2026 List |
| Carfilzomib | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Carnosine | Not on the 2027 List | — | A food or supplement ingredient, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| CART peptide | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Caspofungin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Catestatin | Not on the 2027 List | — | An endogenous chromogranin-A peptide studied in cardiovascular and inflammatory disease; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Cetrorelix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Chromofungin | Not on the 2027 List | — | A chromogranin-A-derived antimicrobial and anti-inflammatory peptide; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Clavanin | Not on the 2027 List | — | Sea-squirt research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Colistin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Colivelin (CLN) | Not on the 2027 List | — | A synthetic neuroprotective hybrid peptide studied as a research compound; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Collagen Peptides | Not on the 2027 List | — | A food or supplement ingredient, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Colostrinin | Not on the 2027 List | — | A food or supplement ingredient, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Copeptin | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Copper Cu 64 dotatate | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Corifollitropin alfa | Not on the 2027 List | — | Not named, and the European Medicines Agency lists Elonva (EU authorisation January 25, 2010) as currently authorised (EMA medicines database, read October 3, 2026), so S0, which reaches only substances with no current approval anywhere, does not apply. Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. 2026: Not on the 2026 List |
| Corticotropin-like intermediate peptide (CLIP) | Not on the 2027 List | — | A natural fragment of ACTH measured in tissue and used in animal research rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Cyclosporine | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Dactinomycin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Dalbavancin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Daptomycin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Dasiglucagon | Not on the 2027 List | — | Not named, and the European Medicines Agency lists Zegalogue (EU authorisation July 24, 2024) as currently authorised (EMA medicines database, read October 3, 2026), so S0, which reaches only substances with no current approval anywhere, does not apply. The US product is discontinued. 2026: Not on the 2026 List |
| Davalintide | Not on the 2027 List | — | An amylin-mimetic peptide for obesity; amylin analogues are not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Degarelix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Deltorphin | Not on the 2027 List | — | An amphibian delta-opioid research peptide; opioid agonists are controlled drugs but the WADA Prohibited List does not name a class covering this research peptide. 2026: Not on the 2026 List |
| Demoxytocin | Not on the 2027 List | — | An oxytocic peptide hormone; not a class WADA lists, and oxytocin itself is not prohibited. 2026: Not on the 2026 List |
| Depreotide | Not on the 2027 List | — | Not named on the List. It is a diagnostic radiotracer, approved in the US in 1999 and later discontinued, used as a single injection for imaging rather than for any therapeutic or performance effect. 2026: Not on the 2026 List |
| Des-acyl Ghrelin (Unacylated Ghrelin) | Not on the 2027 List | — | An endogenous unacylated ghrelin isoform that does not activate GHSR-1a; not a class the WADA Prohibited List names (acylated ghrelin mimetics/GH secretagogues are addressed separately). 2026: Not on the 2026 List |
| Difelikefalin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Drosocin | Not on the 2027 List | — | Fruit-fly research antimicrobial peptide; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Dulaglutide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Ecallantide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Edotreotide | Not on the 2027 List | — | Not named on the List. The gallium-68 form is FDA-approved as a diagnostic, so S0 does not apply to it. 2026: Not on the 2026 List |
| Elagolix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Elamipretide | Not on the 2027 List | — | A mitochondria-targeting tetrapeptide for a rare mitochondrial disease; not a class WADA lists. 2026: Not on the 2026 List |
| Elcatonin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| EM66 | Not on the 2027 List | — | An endogenous secretogranin-II-derived peptide (an anorexigenic neuropeptide and tumour marker); not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Endomorphin-2 (EM-2) | Not on the 2027 List | — | An endogenous mu-opioid tetrapeptide studied as a research compound; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Enfuvirtide | Not on the 2027 List | — | Not named, and the European Medicines Agency lists Fuzeon (EU authorisation May 27, 2003) as currently authorised (EMA medicines database, read October 3, 2026), so S0, which reaches only substances with no current approval anywhere, does not apply. The US product is discontinued. 2026: Not on the 2026 List |
| Enlicitide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Epinecidin-1 | Not on the 2027 List | — | Grouper research antimicrobial/anticancer peptide; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Eptifibatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Esculentin | Not on the 2027 List | — | Frog-skin research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Etelcalcetide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Exenatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Flotufolastat F 18 | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Follitropin alfa | Not on the 2027 List | — | Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. 2026: Not on the 2026 List |
| Follitropin beta | Not on the 2027 List | — | Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. 2026: Not on the 2026 List |
| Follitropin delta | Not on the 2027 List | — | Not named, and the European Medicines Agency lists Rekovelle (EU authorisation December 12, 2016) as currently authorised (EMA medicines database, read October 3, 2026), so S0, which reaches only substances with no current approval anywhere, does not apply. Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. 2026: Not on the 2026 List |
| Galanin-like Peptide (GALP) | Not on the 2027 List | — | An endogenous galanin-family neuropeptide acting at the galanin receptors; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Gallium Ga 68 dotatate | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Ganirelix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| GAWK (Chromogranin B 420-493) | Not on the 2027 List | — | An endogenous chromogranin-B-derived secretory peptide and tumour marker; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Glatiramer Acetate | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Glucagon | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Gomesin | Not on the 2027 List | — | Spider-haemocyte research antimicrobial peptide; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Gozetotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Gramicidin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Hemopressin (Hp) | Not on the 2027 List | — | A hemoglobin-derived peptide acting as a CB1 cannabinoid-receptor inverse agonist; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Hemorphin (Hemorphins) | Not on the 2027 List | — | Endogenous hemoglobin-derived opioid peptides studied as research compounds; not themselves named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Hepcidin | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Homocarnosine | Not on the 2027 List | — | An endogenous brain histidine dipeptide; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Hyaluronic Acid | Not on the 2027 List | — | Not a peptide. 2026: Not on the 2026 List |
| Icatibant | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Icotrokinra | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Indium In 111 pentetreotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| INSL3 | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Katacalcin | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Lanreotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Linaclotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Liraglutide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Lixisenatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Lunasin | Not on the 2027 List | — | A peptide naturally present in soy foods; S0 is written for pharmacological substances. 2026: Not on the 2026 List |
| Lutetium-177 DOTATATE | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Manserin | Not on the 2027 List | — | An endogenous secretogranin-II-derived neuroendocrine peptide; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Mastoparan | Not on the 2027 List | — | A wasp-venom research peptide; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Melatonin | Not on the 2027 List | — | Not named, and the European Medicines Agency lists Circadin (EU authorisation June 29, 2007), Slenyto and Melatonin Neurim as currently authorised (EMA medicines database, read October 3, 2026), so S0, which reaches only substances with no current approval anywhere, does not apply. Also sold as a dietary supplement in the US. 2026: Not on the 2026 List |
| Melphalan Flufenamide | Not on the 2027 List | — | Not named on the List. Authorised in the EU (Pepaxti, 2022), so S0 does not apply. 2026: Not on the 2026 List |
| Metreleptin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Micafungin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Mifamurtide | Not on the 2027 List | — | Not named on the List. Authorised in the EU as Mepact (2009), so the S0 catch-all for substances with no government approval does not apply; it is an immune activator with no performance-enhancing action. 2026: Not on the 2026 List |
| Morphiceptin | Not on the 2027 List | — | A research opioid peptide (beta-casomorphin-4 amide); not itself named on the WADA Prohibited List. Opioids are addressed elsewhere on the List as a drug class. 2026: Not on the 2026 List |
| Motixafortide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Navepegritide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| NERP-2 (Neuroendocrine Regulatory Peptide-2) | Not on the 2027 List | — | Endogenous VGF-derived neuropeptides (orexin-pathway feeding/energy); not themselves a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Neuromedin B | Not on the 2027 List | — | An endogenous bombesin-like neuropeptide acting at the neuromedin B receptor; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Neuromedin N (NN) | Not on the 2027 List | — | An endogenous neurotensin-family peptide acting at neurotensin receptors; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Neuropeptide AF (NPAF) | Not on the 2027 List | — | An endogenous RFamide neuropeptide acting at NPFF receptors; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Neuropeptide B (NPB) | Not on the 2027 List | — | An endogenous neuropeptide acting at the GPR7/GPR8 (NPBWR1/NPBWR2) receptors; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Neuropeptide EI (NEI) | Not on the 2027 List | — | An endogenous prepro-MCH-derived neuropeptide; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Neuropeptide FF (NPFF) | Not on the 2027 List | — | An endogenous RFamide neuropeptide acting at the NPFF receptors; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Neuropeptide W (NPW) | Not on the 2027 List | — | An endogenous neuropeptide acting at the GPR7/GPR8 (NPBWR1/NPBWR2) receptors; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Nisin | Not on the 2027 List | — | A food preservative (E 234; GRAS in the US), not a drug. 2026: Not on the 2026 List |
| Nocistatin (NST) | Not on the 2027 List | — | An endogenous prepronociceptin-derived neuropeptide; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Octreotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Oncocin | Not on the 2027 List | — | Designed research antimicrobial peptide; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Opiorphin | Not on the 2027 List | — | An endogenous salivary analgesic peptide studied as a research compound; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Orforglipron | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Oritavancin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Oxytocin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Palopegteriparatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| PAMP (Proadrenomedullin N-terminal 20 Peptide) | Not on the 2027 List | — | An endogenous adrenomedullin-precursor peptide (hypotensive and sympatho-inhibitory); not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Pancreastatin | Not on the 2027 List | — | An endogenous chromogranin A-derived metabolic peptide; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Pasireotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Pegcetacoplan | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Pentigetide (IgE Pentapeptide) | Not on the 2027 List | — | A synthetic IgE-derived anti-allergy pentapeptide; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Phoenixin | Not on the 2027 List | — | An endogenous neuropeptide studied in reproduction and metabolism; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Piflufolastat F 18 | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Piscidin | Not on the 2027 List | — | Fish research antimicrobial/anticancer peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Plantaricin | Not on the 2027 List | — | Lactic-acid-bacterium food/research bacteriocins; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Plecanatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Pleurocidin | Not on the 2027 List | — | Flounder research antimicrobial/anticancer peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Plitidepsin | Not on the 2027 List | — | Not named on the List. Authorised in Australia for multiple myeloma, so S0 does not apply. 2026: Not on the 2026 List |
| Polaprezinc | Not on the 2027 List | — | Not named on the List. Approved as a medicine in Japan since 1994 (PMID 34721687), so it is outside section S0 (non-approved substances). 2026: Not on the 2026 List |
| Polymyxin B | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Ponericin | Not on the 2027 List | — | Ant-venom research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Prokineticin 1 (EG-VEGF) | Not on the 2027 List | — | An endogenous AVIT-family angiogenic peptide acting at the prokineticin receptors; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Prokineticin 2 | Not on the 2027 List | — | An endogenous AVIT-family neuropeptide acting at the prokineticin receptors; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Prolactin-releasing peptide | Not on the 2027 List | — | Measured in tissue rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Prolyl-Hydroxyproline | Not on the 2027 List | — | A compound found in food or formed from food protein, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Protegrin | Not on the 2027 List | — | Pig-white blood cell research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| PT-141 | Not on the 2027 List | — | 2026: Not on the 2026 List |
| QRFP (26RFa) | Not on the 2027 List | — | An endogenous RFamide neuropeptide acting at the GPR103 receptor; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Relugolix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Rezafungin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| RFRP-3 (GnIH) | Not on the 2027 List | — | An endogenous RFamide neuropeptide acting at GPR147 (NPFFR1); not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Romidepsin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Romiplostim | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Rubiscolin | Not on the 2027 List | — | A food-derived delta-opioid peptide studied as a research compound; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Rusfertide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Salusin-alpha | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Salusin-beta | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Secretin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Secretoneurin (SN) | Not on the 2027 List | — | An endogenous granin-family peptide; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Semaglutide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Serpinin | Not on the 2027 List | — | An endogenous chromogranin-A-derived peptide acting beta-adrenergically on the heart; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Setmelanotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Sialorphin | Not on the 2027 List | — | An endogenous rat analgesic/NEP-inhibitor peptide studied as a research compound; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Snakin | Not on the 2027 List | — | Plant research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Somatostatin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Sovateltide | Not on the 2027 List | — | Not named on the list and outside S0, which covers substances with no current approval by any government health authority: India approved sovateltide in May 2023. 2026: Not on the 2026 List |
| Spinorphin | Not on the 2027 List | — | An endogenous hemoglobin-derived analgesic/anti-inflammatory peptide studied as a research compound; not itself named on the WADA Prohibited List. 2026: Not on the 2026 List |
| SS-31 (Elamipretide) | Not on the 2027 List | — | S0 does not apply: FDA approved elamipretide (Forzinity) in September 2025, and no section of either List names it or a class it belongs to. This row showed S0? until September 27, 2026. 2026: Not on the 2026 List |
| Tachyplesin | Not on the 2027 List | — | Horseshoe-crab research antimicrobial/anticancer peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| TCAP-1 (Teneurin C-terminal Associated Peptide-1) | Not on the 2027 List | — | A teneurin-derived peptide acting as a functional CRF antagonist via the latrophilin receptor; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Technetium Tc 99m Apcitide | Not on the 2027 List | — | Not named on the List. A diagnostic radiotracer approved in the US in 1998 and later discontinued, given once for imaging rather than for any therapeutic or performance effect. 2026: Not on the 2026 List |
| Technetium Tc 99m mertiatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Teduglutide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Teicoplanin | Not on the 2027 List | — | Not named on the List. An antibiotic in clinical use with government approval outside the US, so S0 does not apply. 2026: Not on the 2026 List |
| Telavancin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Temporin | Not on the 2027 List | — | Frog-skin research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Teriparatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Thionin | Not on the 2027 List | — | Plant research antimicrobial peptides; not named on the WADA Prohibited List. 2026: Not on the 2026 List |
| Thyrotropin alfa | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Tirzepatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| TLQP-21 | Not on the 2027 List | — | An endogenous VGF-derived catabolic neuropeptide; not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Trofinetide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Tyrothricin | Not on the 2027 List | — | Not named on the List. A topical antiseptic peptide mixture in licensed medicines outside the US, so S0 does not apply. 2026: Not on the 2026 List |
| Urocortin 3 | Not on the 2027 List | — | An endogenous CRF-family neuropeptide acting at the CRF type 2 receptor; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Urofollitropin | Not on the 2027 List | — | Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. 2026: Not on the 2026 List |
| Urotensin II-related peptide | Not on the 2027 List | — | Measured in blood and tissue rather than given as a medicine; S0 is written for substances used as drugs. 2026: Not on the 2026 List |
| Vancomycin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Vasostatin (Chromogranin A) | Not on the 2027 List | — | An endogenous chromogranin-A-derived vasoinhibitory peptide; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Vipivotide Tetraxetan | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Voclosporin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Vosoritide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| WE-14 | Not on the 2027 List | — | An endogenous chromogranin-A-derived peptide (an autoantigen and tumour marker); not itself a class the WADA Prohibited List names. 2026: Not on the 2026 List |
| Ziconotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Zilucoplan | Not on the 2027 List | — | 2026: Not on the 2026 List |
| αCT1 (Alpha Connexin Carboxyl-Terminus 1) | Not on the 2027 List | — | A connexin43 carboxyl-terminal mimetic peptide for topical wound healing; not a class the WADA Prohibited List names. 2026: Not on the 2026 List |
Monitored, not prohibited
WADA's Monitoring Program tracks substances that are not prohibited, to detect patterns of misuse. For 2027 it includes 9 compounds in our encyclopedia: Buserelin, Gonadorelin, Goserelin, Histrelin, Leuprolide, Nafarelin, Semaglutide, Tirzepatide, Triptorelin. Being monitored is not being prohibited, but it is WADA saying it is watching.
What an athlete should check
- The List in force on the day. A compound can change status between Lists, as dermorphin does for 2027.
- Not named does not mean permitted. S0 catches unapproved substances whether or not anyone has named them, and the 2027 List adds peptides to its examples.
- A prescription is not an exemption. Where a prohibited substance is medically needed, the route is a Therapeutic Use Exemption, which the List itself refers to.
- A label bought outside the regulated supply is not evidence of what is inside. In one study, semaglutide bought online without a prescription contained 28.6% to 38.7% more than its label stated. Our semaglutide entry covers the findings.
- Detection is not the only way a case starts. Labs have published urine methods for BPC-157, TB-500 and the GHRPs, and recent cases were also built on tips, declarations and seized products: do peptides show up on drug tests?
- TB-500 and thymosin β4 are different molecules under one ban. S2.3 covers both, but the human studies were done with the full protein, not the fragment: TB-500 is not thymosin beta-4.
- A ban by mechanism is not proof of effect. MOTS-c is named in S4.4.1 as an AMPK activator on the strength of mouse studies; no published trial has given it to people: what the MOTS-c research shows.
- For athletes, step by step. Our athletes, peptides and testing section covers the compounds athletes ask about, how testing finds peptides, therapeutic use exemptions and contaminated products.
- This page is not a ruling. It reports what the List says and how we read it. An athlete's own anti-doping organisation gives the answer that counts.
Sources
- World Anti-Doping Agency. Prohibited List 2027, approved September 10, 2026, published September 21, 2026, in force January 1, 2027; read September 27, 2026. WADA
- World Anti-Doping Agency. Prohibited List 2027: Summary of Major Modifications and Explanatory Notes. WADA
- World Anti-Doping Agency. 2027 Monitoring Program. WADA
- World Anti-Doping Agency. Prohibited List 2026, in force January 1, 2026; read September 27, 2026. WADA
- Ashraf AR et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription. J Med Internet Res 2024;26:e65440. PMID 39509151. PubMed
- Grey Peptides dataset: each entry's WADA record for both years, with its section, the List's wording where named, and the date reviewed. Dataset · Regulatory tracker · Our report on the 2027 List
This page reports the Prohibited List and our reading of it. It is not legal advice or an anti-doping ruling.